> News > News

The Application of 5MTHF (MAGNAFOLATE®) in the Field of Antidepressants & Alzheimer's Disease

2022-01-17

There will be 1 case of dementia around the world every 3 seconds.

About 50 million people suffer from dementia worldwide in 2018.
And this number will increase to 152 million by 2050, three times as many cases as now.
It is estimated that global cost of social dementia is $1 trillion in 2018, and the figure will rise to $2 trillion by 2030.

Statistically, depression affects more than 300 million people worldwide now, nearly half of whom live in Southeast Asia and the Western Pacific, including India and China.

By 2017, more than 54 million people in China were suffering from depression. Depression causes direct or indirect economic losses of nearly 64 billion yuan every year in China.

According to the WTO, nearly 1 billion people worldwide shall have mental health problems after the COVID-19.

1.Hyperhomocysteinemia (HHcy) is an important potential risk factor for cardiovascular and cerebrovascular disease, depression, senile dementia and other diseases.

2.Hcy has a direct toxic effect on n-methyl-D-aspartic glutamate receptors in the central nervous system. Dietary management with L-Methylfolate may be effective in reducing elevated homocysteine levels and reduce direct toxic and side effects on the nervous system.

3. Lowering homocysteine levels has been shown to slow the atrophication of areas of the brain specifically effected by Alzheimer’s Dementia by up to 9-fold (Douaud, 2013).

4. A folate regime conferred the performance of someone younger by (Durga, 2007):

4.7 years for memory

1.5 years for global cognitive function

6.7 years for delayed recall

L-Methylfolate can repair the Hcy circulation and produce enough SAM (S-adenosine methionine) to normalize the methylation of bioamines and phospholipids in the central nervous system, thus promoting the synthesis of 5-ht.

Through regulation, tetrahydrobiopterin (BH4) is produced to affect the synthesis of neurotransmitters. Tetrahydrobiopterin (BH4) is an essential nutrient cofactor for the formation of monoamine neurotransmitters such as serotonin, dopamine and norepinephrine.

A clinical study of L-Methylfolate for antidepressants conducted by ALFASIGMA in US has demonstrated the benefit of a daily supplement of 15mg of LMF for patients with and without SSRI partial response and major depression.

50% among patients who were given LMF at 15mg/day had a reduction in depressive symptoms within 30 days.

84% had a significantly relieved.

In the USA, our partner Methyl-Life™ is honored to have been the first company offer this uniquely superior form of L-Methylfolate to the customer over 5 years.

Recent studies show that Magnafolate® PRO significantly greater purity, stability and potency results when compared against competing other brands.

Magnafolate® ,the Manufacturers & Supplier of active folate.

Previous:Choosing Magnafolate, best care for your babies!

Next:What is L-Methylfolate?